Moderna Inc's coronavirus vaccine on Friday became the second to receive emergency use authorization (EUA) from the U.S. Food and Drug Administration, welcome news to a nation with a staggering COVID-19 death toll of over 311,000 lives lost.
The U.S. Food and Drug Administration gave Moderna the green light on Friday night to provide doses of its coronavirus vaccine to millions of Americans for inoculation.
Moderna's vaccine became the second to the receive emergency use authorization, or EUA -- welcome news to a nation with a staggering COVID-19 death toll of over 311,000 lives lost.
The FDA announced the authorization the day after the agency's panel of outside experts endorsed its use.
The authorization follows an EUA granted for a similar vaccine from Pfizer and German partner BioNTech that has been put into the arms of thousands of U.S. healthcare workers this week in a massive nationwide rollout.
Johnson & Johnson will ship nearly 4 million doses of its newly authorized single-dose COVID-19 vaccine around the United States this week, but a top executive said on Monday that the next round of deliveries is contingent on regulatory approvals at a new plant. Gloria Tso reports.
The US just added another powerful tool against Covid-19 to its inventory: a third vaccine. Johnson & Johnson is shipping nearly 4 million doses around the country today. CNN’s Pete Muntean is outside a UPS facility in Kentucky.
[NFA] Dr. Anthony Fauci, the top U.S. infectious disease official, on Sunday urged Americans to take any of the three approved COVID-19 vaccines available to them, including the newly-authorized single-shot vaccine from Johnson & Johnson. Lisa Bernhard produced this report.
Johnson & Johnson said on Thursday it has asked U.S. health regulators to authorize its single-dose COVID-19 vaccine for emergency use, and it will apply to European authorities in coming weeks. Gloria Tso reports.
A fourth coronavirus vaccine could be approved for use in the UK within weeks as late-stage trials suggested it was 89% effective in preventing Covid-19.
The UK has secured 60 million doses of the Novavax jab, which is believed to offer protection against the new UK and South African variants.
Two vaccines have already been rolled out in the UK – from Pfizer and Oxford/AstraZeneca – while a third from Moderna has been approved for use.
The Novavax jab will be delivered in the second half of 2021 if it receives MHRA approval. Report by Avagninag. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn
The Biden administration will purchase 200 million more coronavirus vaccines and funnel more to states now, in a bid to deliver on the president's promise to curb the pandemic. This report produced by Jillian Kitchener.
New data shows that a single jab of either the Oxford-AstraZeneca or the Pfizer-BioNTech Covid jab reduces the chance of needing hospital treatment by over 80%. Health Secretary Matt Hancock told a Downing Street press conference that "a single shot of either the Oxford/AstraZeneca vaccine or of the Pfizer vaccine works against severe infection among the over-70s with a more than 80% reduction in hospitalisations". He added that the data shows "the protection that you get from catching Covid 35 days after a first jab is even slightly better for the Oxford jab than for Pfizer, albeit both results are clearly very strong."
Report by Thomasl. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn
Initial deliveries of the newly approved Johnson & Johnson COVID-19 vaccine should start on Tuesday, senior Biden administration officials said on Sunday, saying they hoped to boost lagging vaccination rates among minorities. Bryan Wood reports.
A single dose of the Pfizer-BioNTech coronavirus vaccine reduces the risk of asymptomatic infections, helping to stem transmission, research suggests.The UK has approved three coronavirus jabs – Pfizer-BioNTech, AstraZeneca-University of Oxford and Moderna – after studies demonstrated they significantly ward off severe disease.With not everyone able to be immunised, or producing a strong immune response as a result of their vaccination, questions lingered as to whether the jabs prevented the infection itself.Asymptomatic infections are particularly important amid the pandemic, given these individuals do not know to isolate and may unwittingly transmit the coronavirus even when they speak.To learn more, medics from the Cambridge University Hospitals NHS Foundation Trust (CUH) swabbed the site's vaccinated and unvaccinated healthcare workers over two weeks.Results suggest the risk of an asymptomatic infection decreases by four times more than 12 days after a worker received the Pfizer-BioNTech jab.
New research suggests people of all ages who have had two jabs of the Pfizer-BioNTech coronavirus vaccine produce high numbers of antibodies.
The Imperial College London and Ipsos Mori study, React-2, said data shows that 87.9% of people over the age of 80 tested positive for antibodies after two doses.
That figure rose to 95.5% for those under 60 and 100% in those aged under 30.
However, researchers warned there was not enough data to say how protected someone may be from the virus based on a positive antibody test result, and it did not mean they were immune. Report by Avagninag. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn
President Joe Biden on Tuesday ordered U.S. states to prioritize COVID-19 vaccinations for teachers to ensure children could return to school quickly and safely, and called for every educator to receive at least one shot by the end of March. Gloria Tso reports.
Health Secretary Matt Hancock said there was “exciting new data” showing the effectiveness of the vaccines.He told a Downing Street press conference the data showed that “a single shot of either the Oxford/AstraZeneca vaccine or of the Pfizer vaccine works against severe infection among the over-70s with a more than 80% reduction in hospitalisations”.
Credit: PA - Press Association STUDIO Duration: 01:00Published